CD40LG and multiple sclerosis: In a phase 2 trial, frexalimab, an anti-CD40L humanized IgG1 monoclonal antibody lacking the FcγRIIA-activating domain, has shown promising results in participants with multiple sclerosis and is also under development for the treatment of SjD32.